© 2022 MJH Life Sciences and Center for Biosimilars®. All rights reserved.
© 2022 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
Sonia T. Oskouei, PharmD, BCMAS, DPLA, is vice president of Biosimilars for Cardinal Health.
January 16, 2021
Samsung Bioepis has filed for FDA approval for a ranibizumab biosimilar candidate (SB11), and more ophthalmology biosimilars are in the pipeline.
July 04, 2020
Cardinal Health Specialty Solutions has produced a Rheumatology Insights report that includes results from a survey of over 100 US-based rheumatologists on their perceptions and experiences with biosimilars in rheumatology thus far.